Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) established initial surge of 0.86% at $30.32, as the Stock market unbolted on Thursday, before settling in for the price of $30.06 at the close. Taking a more long-term approach, TEVA posted a 52-week range of $12.47-$30.44.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -9.65%. Meanwhile, its Annual Earning per share during the time was -9.65%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 6.22%. This publicly-traded company’s shares outstanding now amounts to $1.15 billion, simultaneously with a float of $1.14 billion. The organization now has a market capitalization sitting at $34.77 billion. At the time of writing, stock’s 50-day Moving Average stood at $24.11, while the 200-day Moving Average is $18.68.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Teva- Pharmaceutical Industries Ltd. ADR industry. Teva- Pharmaceutical Industries Ltd. ADR’s current insider ownership accounts for 0.16%, in contrast to 58.27% institutional ownership. According to the most recent insider trade that took place on Dec 16 ’25, this organization’s Chief Accounting Officer sold 12,300 shares at the rate of 30.20, making the entire transaction reach 371,504 in total value, affecting insider ownership by 5,650. Preceding that transaction, on Dec 16 ’25, Company’s Director sold 77,400 for 30.24, making the whole transaction’s value amount to 2,340,646. This particular insider is now the holder of 367,600 in total.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.57 per share during the current fiscal year.
Teva- Pharmaceutical Industries Ltd. ADR’s EPS increase for this current 12-month fiscal period is 6.22% and is forecasted to reach 2.75 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 7.76% through the next 5 years, which can be compared against the -9.65% growth it accomplished over the previous five years trading on the market.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Trading Performance Indicators
Let’s observe the current performance indicators for Teva- Pharmaceutical Industries Ltd. ADR (TEVA). It’s Quick Ratio in the last reported quarter now stands at 0.82. Alongside those numbers, its PE Ratio stands at $49.52, and its Beta score is 0.65. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.06. Similarly, its price to free cash flow for trailing twelve months is now 138.43.
In the same vein, TEVA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.61, a figure that is expected to reach 0.65 in the next quarter, and analysts are predicting that it will be 2.75 at the market close of one year from today.
Technical Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
Now, what If we examine the latest scores posted by [Teva- Pharmaceutical Industries Ltd. ADR, TEVA]. During the last 5-days, its volume was lower the volume of 11.75 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 88.62% While, its Average True Range was 81.91.
Raw Stochastic average of Teva- Pharmaceutical Industries Ltd. ADR (TEVA) in the period of the previous 100 days is set at 99.22%, which indicates a major rise in contrast to 96.98% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.64 that was higher than 0.61 volatility it exhibited in the past 100-days period.
